Protocol for a Randomized Controlled Trial Comparing Intravitreal Brolucizumab with Placebo for Chronic Central Serous Chorioretinopathy with Persistent Macular Fluid Without Choroidal Neovascular Membrane – BRICS Report #1
The results of this study will provide an understanding of the efficacy and safety of brolucizumab in achieving fluid resolution in chronic CSCR without CNVM.
Authors
- Srinivas R. Sadda (ORCID: https://orcid.org/0000-0002-4939-3306)
- Mudit Tyagi (ORCID: https://orcid.org/0000-0001-9211-917X)
- Nikitha Gurram Reddy (ORCID: https://orcid.org/0000-0001-6523-9248)
- Saarang Hansraj (ORCID: https://orcid.org/0000-0002-9553-4560)
- Srishti Ramamurthy (ORCID: https://orcid.org/0000-0003-3139-608X)
- Umesh Chandra Behera (ORCID: https://orcid.org/0000-0001-6812-1894)
- Sobha Sivaprasad (ORCID: https://orcid.org/0000-0001-8952-0659)
- Jay Kumar Chhablani (ORCID: https://orcid.org/0000-0003-1772-3558)
- Raja Narayanan (ORCID: https://orcid.org/0000-0001-9688-5859)
- Ritesh Narula (ORCID: https://orcid.org/0000-0003-0192-0178)
Institutions
- Moorfields Eye Hospital NHS Foundation Trust (GB)
- University of California, Los Angeles (US)
- University of Pittsburgh (US)
- L V Prasad Eye Institute (IN)
- Doheny Eye Institute (US)
- Moorfields Eye Hospital (GB)
- Retina Institute (US)
- University College London (GB)
Publication Details
- Journal
- Seminars in Ophthalmology
- Published
- 2025-03-28
- DOI
- https://doi.org/10.1080/08820538.2025.2478072
- Citations
- 1
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.71
Funders
- Hyderabad Eye Research Foundation